Gelesis Holdings Inc
Change company Symbol lookup
Select an option...
GLS Gelesis Holdings Inc
NRUC National Rural Utilities Cooperative Finance Corp
UPS United Parcel Service Inc
BOLT Bolt Biotherapeutics Inc
EIX Edison International
EM Smart Share Global Ltd
WTW Willis Towers Watson PLC
DSU BlackRock Debt Strategies Fund Inc
TRTN-A Triton International Ltd
RNG RingCentral Inc
Go

Company profile

Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. It focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate include GS200, provides additional potential health benefits in prediabetics and type two diabetics. It is also developing GS300, treatment for NAFLD and NASH and GS500, for the treatment of FC.

Closing Price
$4.73
Day's Change
-0.53 (-10.08%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.47
Day's Low
4.71
Volume
(Light)
Volume:
116,965

10-day average volume:
214,509
116,965

Display:

Providers:

UpdateCancel
6 providers
January 14, 2022
PureTech Founded Entity Gelesis, the Maker of Plenity(R) for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar

--Gelesis will begin trading on the New York Stock Exchange as "GLS" on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage...(BusinessWire)

January 13, 2022
Gelesis(R), the Maker of Plenity(R) for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar

--Gelesis will begin trading on the New York Stock Exchange as "GLS" on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 Gelesis, the maker of Plenity(R), an FDA-cleared weight management approach, announced today the...(BusinessWire)

January 05, 2022
Gelesis Adds Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee

--Bauerlein joins Gelesis' board of industry veterans and luminaries who have deep expertise in direct-to-consumer brands, healthcare, and biotechnology --Registration Statement filed in connection with proposed business combination between Gelesis...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.